If our results can be translated to humans, they suggest a novel strategy of combining poziotinib with certain anticancer drugs to treat CRC patients with MDR cancer due to the overexpression of ABCG2 and/or ABCB1 transporters. The gene discussed is ABCG2; the disease is cancer.